Patent Expiries Will Contribute to Growth Rate Decline in Respiratory Therapeutics Market:

LONDON--(BUSINESS WIRE)-- The global market for respiratory therapeutics is anticipating growth of over 3% CAGR to 2017, at which point it is expected to be worth $37.4 billion, according to a new research report available from Nearly 50 million incidences of respiratory disorders were recorded in 2010.

Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and Pirfenidone May Offset Negative Effect of Patent Expiries

The respiratory disorders therapeutics market will witness a decline in growth rates over the next few years, following patent expiries for a number of drugs and the subsequent entrance of generic competitors. By 2017 it is expected that branded medication will hold just 51% of the respiratory disorders treatment market.

Upcoming patent expiries of note include: Advair (fluticasone and salmeterol), Nasonex (mometasone furoate monohydrate), Rhinocort (budesonide), Symbicort (budesonide and formoterol inhalation), Singulair (montelukast) and Tracleer (bosentan).

Although growth in the respiratory therapeutics market will be subdued over the reporting period, it will be bolstered by the release of new treatments - Indacaterol, Riociguat (BAY 63-2521) and VX-770.

As competition intensifies, there will be an increase in the number of global mergers and acquisitions within the respiratory therapeutics industry, as companies tactically position themselves in prominent market positions. In 2011, we have seen the acquisition of Clinical Data by Forest Laboratories, in a deal worth $1,200 million. The majority of M&A transactions since 2004 have been valued at less than $200 million. During the reporting period the majority (45%) of consolidation activity involved companies in the US.

The September 2011 report provides a comprehensive overview of the respiratory therapeutic treatment market in Europe, Japan and the US. It includes analysis of the competitive landscape, key players and their products, treatment methods, and M&A activity. The treatments and therapy costs for the seven most prevalent respiratory disorders are analysed at length: asthma, COPD, pulmonary arterial hypertension, cystic fibrosis, allergic rhinitis, idiopathic pulmonary fibrosis and bronchitis.

Report Details:


Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Other Health